Marshall Wace
TTPH

Marshall Wace’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Marshall Wace’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,790
Closed -$927K – 1908
2018
Q3 		$927K Buy
+16,790
New +$1.07M 0.01% 826

Other funds holding TTPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace's TTPH Position: Q4 2018 in Review

Marshall Wace sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q4 2018, closing a stake of 16,790 shares — an estimated $927K sold.

Marshall Wace first reported a position in TTPH in Q3 2018 and held it in 1 quarter. The position peaked at $927K in Q3 2018. 86 funds tracked by Wall St. Rank hold TTPH as of Q4 2018.

  • Marshall Wace reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Marshall Wace sold 16,790 Tetraphase Pharmaceuticals, Inc. shares in Q4 2018, an estimated $927K.
  • Marshall Wace first reported a position in Tetraphase Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • Marshall Wace's Tetraphase Pharmaceuticals, Inc. position peaked at $927K in Q3 2018.
  • 86 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q4 2018.

Based on Marshall Wace's 13F filing for Q4 2018, filed 14 Feb 2019.